Ticagrelor is labelled as a reversible, direct‐acting platelet P2Y12 receptor (P2Y12R) antagonist that is indicated clinically for the prevention of thrombotic events in patients with acute coronary syndrome (ACS). Here, P2RY12 is linked to acute coronary syndrome.